Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Sagimet Biosciences (Nasdaq: SGMT) announced that management will participate in the H.C.
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A fireside chat at 2:00 p.m. ET will be webcast live and archived for 90 days on Sagimet’s website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SGMT
On May 13, the day this news came out, SGMT closed 0.65% below the previous close.
Data tracked by StockTitan Argus for the May 13 session.
Key Figures
- Conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- Fireside chat time
- 2:00 p.m. ET
- Scheduled investor fireside chat at conference
- Replay availability
- 90 days
- Archived webcast replay duration on Sagimet’s investor website
Historical Context
-
Q1 2026 results, $175M financing, extended acne cash runway and lower net loss.
-
Preclinical mechanism-of-action data for FASN inhibitors supporting planned Phase 3 acne trial.
-
Pricing of $175M Series A stock offering at $6.00 per share for acne programs.
-
Dermatology-focused strategy, planned US Phase 3 acne trial and positive China Phase 3 safety.
-
Appointment of new Chief Medical Officer and inducement stock option grant.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link here).
A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.